CN102300854B - 作为抗癌剂的苯并噻唑衍生物 - Google Patents

作为抗癌剂的苯并噻唑衍生物 Download PDF

Info

Publication number
CN102300854B
CN102300854B CN200980155786.1A CN200980155786A CN102300854B CN 102300854 B CN102300854 B CN 102300854B CN 200980155786 A CN200980155786 A CN 200980155786A CN 102300854 B CN102300854 B CN 102300854B
Authority
CN
China
Prior art keywords
compound
cyano
acid
group
ethyl acetate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980155786.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN102300854A (zh
Inventor
冈庭正格
高木辉文
广瀬雅朗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42026212&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102300854(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of CN102300854A publication Critical patent/CN102300854A/zh
Application granted granted Critical
Publication of CN102300854B publication Critical patent/CN102300854B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN200980155786.1A 2008-12-02 2009-12-01 作为抗癌剂的苯并噻唑衍生物 Expired - Fee Related CN102300854B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2008307581 2008-12-02
JP2008-307581 2008-12-02
JP2009125256 2009-05-25
JP2009-125256 2009-05-25
PCT/JP2009/070447 WO2010064722A1 (en) 2008-12-02 2009-12-01 Benzothiazole derivatives as anticancer agents

Publications (2)

Publication Number Publication Date
CN102300854A CN102300854A (zh) 2011-12-28
CN102300854B true CN102300854B (zh) 2015-01-07

Family

ID=42026212

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980155786.1A Expired - Fee Related CN102300854B (zh) 2008-12-02 2009-12-01 作为抗癌剂的苯并噻唑衍生物

Country Status (40)

Country Link
US (2) US8143258B2 (https=)
EP (1) EP2358689B9 (https=)
JP (1) JP5640014B2 (https=)
KR (1) KR101639092B1 (https=)
CN (1) CN102300854B (https=)
AR (1) AR074435A1 (https=)
AU (1) AU2009323274B2 (https=)
BR (1) BRPI0922109A2 (https=)
CA (1) CA2745144C (https=)
CL (1) CL2011001299A1 (https=)
CO (1) CO6400140A2 (https=)
CR (1) CR20110366A (https=)
CY (1) CY1117178T1 (https=)
DK (1) DK2358689T5 (https=)
DO (1) DOP2011000165A (https=)
EA (1) EA019447B1 (https=)
EC (1) ECSP11011165A (https=)
ES (1) ES2557304T3 (https=)
GE (1) GEP20146003B (https=)
HR (1) HRP20151370T1 (https=)
HU (1) HUE026491T4 (https=)
IL (1) IL213184A0 (https=)
JO (1) JO3101B1 (https=)
MA (1) MA32911B1 (https=)
ME (1) ME02331B (https=)
MX (1) MX2011005836A (https=)
MY (1) MY150989A (https=)
NZ (1) NZ593759A (https=)
PE (1) PE20110588A1 (https=)
PL (1) PL2358689T3 (https=)
PT (1) PT2358689E (https=)
RS (1) RS54370B9 (https=)
SG (1) SG171426A1 (https=)
SI (1) SI2358689T1 (https=)
SM (1) SMT201500316B (https=)
TN (1) TN2011000280A1 (https=)
TW (1) TWI436987B (https=)
UY (1) UY32281A (https=)
WO (1) WO2010064722A1 (https=)
ZA (1) ZA201104659B (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2008001626A1 (es) * 2007-06-05 2009-06-05 Takeda Pharmaceuticals Co Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer.
EP2181987B9 (en) * 2007-08-23 2014-09-03 Takeda Pharmaceutical Company Limited 2-Carbonylaminobenzothiazoles and their use for the prophylaxis and treatment of cancer
WO2009136663A1 (en) * 2008-05-08 2009-11-12 Takeda Pharmaceutical Company Limited Fused heterocyclic derivatives and use thereof
US8697874B2 (en) 2008-12-01 2014-04-15 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US9725427B2 (en) 2012-03-16 2017-08-08 Biohaven Pharmaceutical Holding Company Limited Prodrugs of riluzole and their method of use
CA2868954A1 (en) * 2012-03-30 2013-10-03 Takeda Pharmaceutical Company Limited Administration of a raf inhibitor and a mek inhibitor in the treatment of melanoma
ES2877570T3 (es) 2012-08-22 2021-11-17 Univ Cornell Métodos para inhibir fascina
EA029412B1 (ru) 2013-06-28 2018-03-30 Бейджин, Лтд. Конденсированные трициклические соединения мочевины в качестве ингибиторов киназы raf и/или димера киназы raf
EP3013797B1 (en) 2013-06-28 2018-01-03 BeiGene, Ltd. Fused tricyclic amide compounds as multiple kinase inhibitors
CN103382190B (zh) * 2013-07-16 2015-01-14 浙江医药高等专科学校 一类噻唑并环己烷类化合物、其制备方法和用途
CN103435572B (zh) * 2013-07-16 2015-02-04 浙江医药高等专科学校 噻唑并环己烷类化合物、其制备方法和抗肿瘤用途
CN103435573B (zh) * 2013-07-16 2015-04-01 浙江医药高等专科学校 苄基取代的噻唑并环己烷类化合物、其制备方法和用途
CN103408541B (zh) * 2013-07-16 2015-04-01 浙江医药高等专科学校 吲哚取代的噻唑并环己烷类化合物、及其抗肿瘤用途
US9573946B2 (en) 2014-02-20 2017-02-21 Novita Pharmaceuticals, Inc. Compounds and methods for inhibiting fascin
EP3169815B1 (en) 2014-07-15 2020-12-23 Ontario Institute For Cancer Research Methods and devices for predicting anthracycline treatment efficacy
CN107405348B (zh) * 2014-12-23 2021-06-11 点疗法-1公司 Raf抑制剂与紫杉烷的组合
WO2017066664A1 (en) * 2015-10-16 2017-04-20 Millennium Pharmaceuticals, Inc. Combination therapy including a raf inhibitor for the treatment of colorectal cancer
WO2017165742A1 (en) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments
WO2017165491A1 (en) * 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Use of a pd-1 antagonist and a raf inhibitor in the treatment of cancer
JP7069032B2 (ja) 2016-03-24 2022-05-17 ミレニアム ファーマシューティカルズ， インコーポレイテッド がん免疫治療における胃腸の免疫関連有害事象の治療方法
CN109053630B (zh) * 2018-08-22 2022-04-01 中国人民解放军第二军医大学 一种苯并噻唑类衍生物及其用途
EP3877371A4 (en) 2018-11-07 2022-07-27 Dana-Farber Cancer Institute, Inc. IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF
US12522583B2 (en) 2018-11-07 2026-01-13 Dana-Farber Cancer Institute, Inc. Benzimidazole derivatives and aza-benzimidazole derivatives as Janus kinase 2 inhibitors and uses thereof
EP3876939A4 (en) 2018-11-07 2022-08-10 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
TWI849043B (zh) 2019-01-25 2024-07-21 英屬開曼群島商百濟神州有限公司 B-raf激酶二聚體抑制劑之穩定固體分散體、製備方法及其用途
WO2020232445A1 (en) * 2019-05-16 2020-11-19 The Regents Of The University Of California Modulators of pyrimidine nucleotide biosynthetic pathways
US11691963B2 (en) 2020-05-06 2023-07-04 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
CN112094248B (zh) * 2020-09-17 2023-05-12 中国人民解放军海军军医大学 一种取代苯并噻唑类化合物及其用途
US12043632B2 (en) 2020-12-23 2024-07-23 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
WO2023086319A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-he tero aryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
US12162881B2 (en) 2021-11-09 2024-12-10 Ajax Therapeutics, Inc. Forms and compositions of inhibitors of JAK2
CN115724837B (zh) * 2022-10-26 2024-07-23 中国人民解放军海军军医大学 一种抑制程序性细胞坏死的苯并噻唑衍生物及其应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002044156A2 (en) * 2000-11-29 2002-06-06 Glaxo Group Limited Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
CN1655779A (zh) * 2002-03-29 2005-08-17 希龙公司 取代的吲哚及其作为Raf激酶抑制剂的应用
CN1721397A (zh) * 1999-01-13 2006-01-18 拜尔有限公司 用ω－羧基芳基取代的二苯脲作为raf激酶抑制剂
US20060241301A1 (en) * 2003-07-30 2006-10-26 Gunter Hoelzemann Urea derivatives and their use as tyrosinkinase inhibitors
CN101106990A (zh) * 2005-01-26 2008-01-16 Irm责任有限公司 用作蛋白激酶抑制剂的化合物和组合物
CN101220024A (zh) * 2007-12-11 2008-07-16 杜晓敏 一组抑制激酶的抗癌化合物
CN101260106A (zh) * 2007-03-06 2008-09-10 中国药科大学 Raf激酶抑制剂及其制备方法和用途

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2399026A (en) * 1941-02-06 1946-04-23 Chem Ind Basel Amides of 2-aminoarylenethiazoles
US4096264A (en) 1975-12-09 1978-06-20 Merck & Co., Inc. Certain substituted imidazo [1,2-a] pyridines
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
HUP0004024A3 (en) 1997-09-26 2001-10-29 Zentaris Gmbh Azabenzimidazole-based compounds, process for their preparation and pharmaceutical composition thereof
EP1140840B1 (en) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7928239B2 (en) 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
EP1158985B1 (en) 1999-01-13 2011-12-28 Bayer HealthCare LLC OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
ATE356117T1 (de) * 1999-01-22 2007-03-15 Kirin Brewery Derivate des n-((chinolinyl)oxy)-phenyl)- harnstoffs und des n-((chinazolinyl)oxy)-phenyl)- harnstoffs mit antitumor aktivität
BR0012046A (pt) * 1999-07-01 2002-05-14 Ajinomoto Kk Composto heterocìclico, composição farmacêutica, inibidor de ativação de ap-1 ou um inibidor da ativação de nf-kappab, inibidor da produção de citocina inflamatória, e, inibidor da produção de metaloprotease de matriz ou inibidor da expressão do fator de adesão de célula inflamatória
KR100881105B1 (ko) 1999-11-05 2009-02-02 아스트라제네카 아베 Ｖｅｇｆ 억제제로서의 퀴나졸린 유도체
KR20020084116A (ko) 2000-02-07 2002-11-04 애보트 게엠베하 운트 콤파니 카게 2-벤조티아졸릴 우레아 유도체 및 이의 단백질 키나제억제제로서의 용도
JP3663382B2 (ja) 2000-02-15 2005-06-22 スージェン・インコーポレーテッド ピロール置換２−インドリノン蛋白質キナーゼ阻害剤
GB0005357D0 (en) 2000-03-06 2000-04-26 Smithkline Beecham Plc Compounds
ATE266022T1 (de) 2000-03-06 2004-05-15 Smithkline Beecham Plc Imidazol derivate als raf kinase inhibitoren
AU2001281817B2 (en) 2000-06-21 2005-11-24 F. Hoffmann-La Roche Ag Benzothiazole derivatives
US7199137B2 (en) 2000-09-21 2007-04-03 Smithkline Beecham Plc Imidazole derivatives as Raf kinase inhibitors
AU9598601A (en) 2000-10-20 2002-04-29 Eisai Co Ltd Nitrogenous aromatic ring compounds
GB0112348D0 (en) 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
US7375105B2 (en) 2001-09-05 2008-05-20 Smithkline Beecham P.L.C. Pyridine substituted furan derivatives as Raf kinase inhibitors
GB0121488D0 (en) 2001-09-05 2001-10-24 Smithkline Beecham Plc Compounds
US20040192689A1 (en) 2001-09-05 2004-09-30 Dean David Kenneth Heterocycle-carboxamide derivatives as raf kinase inhibitors
GB0121494D0 (en) 2001-09-05 2001-10-24 Smithkline Beecham Plc Compounds
AU2003220970A1 (en) 2002-03-01 2003-09-16 Smithkline Beecham Corporation Diamino-pyrimidines and their use as angiogenesis inhibitors
US8299108B2 (en) 2002-03-29 2012-10-30 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of raf kinase
WO2004087153A2 (en) 2003-03-28 2004-10-14 Chiron Corporation Use of organic compounds for immunopotentiation
US7378233B2 (en) * 2003-04-12 2008-05-27 The Johns Hopkins University BRAF mutation T1796A in thyroid cancers
DE10337942A1 (de) * 2003-08-18 2005-03-17 Merck Patent Gmbh Aminobenzimidazolderivate
KR20060118472A (ko) 2003-10-16 2006-11-23 카이론 코포레이션 치환 벤자졸 및 ｒａｆ 키나아제의 저해제로서 그것의 사용
WO2005112932A2 (en) 2004-05-07 2005-12-01 Exelixis, Inc. Raf modulators and methods of use
MX2007001155A (es) 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
KR20060079098A (ko) 2004-12-31 2006-07-05 주식회사 엘지생명과학 신규한([1,3]티아졸로[5,4-ｂ]피리딘-2-일)-2-카르복사마이드유도체
WO2006076376A1 (en) 2005-01-11 2006-07-20 Medicinova, Inc. Topical treatment of solid tumors and ocular neovascularization
JP4033409B1 (ja) 2005-07-11 2008-01-16 田辺三菱製薬株式会社 オキシム誘導体及びその製法
TWI387592B (zh) 2005-08-30 2013-03-01 Novartis Ag 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法
GT200600429A (es) 2005-09-30 2007-04-30 Compuestos organicos
WO2007058482A1 (en) 2005-11-16 2007-05-24 Lg Life Sciences, Ltd. Novel inhibitors of protein kinase
CA2649288C (en) 2006-04-19 2015-11-24 Novartis Ag 6-o-substituted benzoxazole and benzothiazole compounds and methods of inhibiting csf-1r signaling
EP2058309A4 (en) 2006-08-04 2010-12-22 Takeda Pharmaceutical CONDENSED HETEROCYCLIC COMPOUND
AU2007279595A1 (en) 2006-08-04 2008-02-07 Takeda Pharmaceutical Company Limited Fused heterocyclic derivative and use thereof
WO2008084873A1 (ja) 2007-01-10 2008-07-17 Mitsubishi Tanabe Pharma Corporation オキシム誘導体
JP4328820B2 (ja) 2007-01-10 2009-09-09 田辺三菱製薬株式会社 医薬組成物
WO2008125633A2 (en) 2007-04-13 2008-10-23 Rikshospitalet - Radiumhospitalet Hf Egfr inhibitors for treatment and diagnosis of metastatic prostate cancer
EP2162552A4 (en) 2007-05-11 2010-06-30 Univ Johns Hopkins BIOMARKER FOR MELANOME
BRPI0811097A2 (pt) 2007-05-23 2014-12-09 Novartis Ag Inibidores de raf para o tratamento de câncer de tireoide
CL2008001626A1 (es) 2007-06-05 2009-06-05 Takeda Pharmaceuticals Co Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer.
JP2008307581A (ja) 2007-06-15 2008-12-25 Sanyo Special Steel Co Ltd 管材の洗浄装置
EP2181987B9 (en) 2007-08-23 2014-09-03 Takeda Pharmaceutical Company Limited 2-Carbonylaminobenzothiazoles and their use for the prophylaxis and treatment of cancer
JP5350247B2 (ja) 2007-08-29 2013-11-27 武田薬品工業株式会社 複素環化合物およびその用途
WO2009028655A1 (ja) 2007-08-30 2009-03-05 Takeda Pharmaceutical Company Limited 複素環化合物およびその用途
JP2009125256A (ja) 2007-11-22 2009-06-11 Kandado:Kk 安眠枕
WO2009099991A2 (en) 2008-01-31 2009-08-13 The Brigham And Women's Hospital, Inc. Treatment of cancer
US20090275546A1 (en) * 2008-04-10 2009-11-05 Istituto Superiore Di Sanita Diagnostic tests and personalized treatment regimes for cancer stem cells
WO2009136663A1 (en) 2008-05-08 2009-11-12 Takeda Pharmaceutical Company Limited Fused heterocyclic derivatives and use thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1721397A (zh) * 1999-01-13 2006-01-18 拜尔有限公司 用ω－羧基芳基取代的二苯脲作为raf激酶抑制剂
WO2002044156A2 (en) * 2000-11-29 2002-06-06 Glaxo Group Limited Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
CN1655779A (zh) * 2002-03-29 2005-08-17 希龙公司 取代的吲哚及其作为Raf激酶抑制剂的应用
US20060241301A1 (en) * 2003-07-30 2006-10-26 Gunter Hoelzemann Urea derivatives and their use as tyrosinkinase inhibitors
CN101106990A (zh) * 2005-01-26 2008-01-16 Irm责任有限公司 用作蛋白激酶抑制剂的化合物和组合物
CN101260106A (zh) * 2007-03-06 2008-09-10 中国药科大学 Raf激酶抑制剂及其制备方法和用途
CN101220024A (zh) * 2007-12-11 2008-07-16 杜晓敏 一组抑制激酶的抗癌化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
抗肿瘤药物Raf激酶抑制剂的研究进展;焦宇 等;《海峡药学》;20070831;第19卷(第8期);1-5 *

Also Published As

Publication number Publication date
JO3101B1 (ar) 2017-09-20
GEP20146003B (en) 2014-01-10
DK2358689T5 (en) 2016-10-10
TN2011000280A1 (en) 2012-12-17
IL213184A0 (en) 2011-07-31
US8497274B2 (en) 2013-07-30
EA201170735A1 (ru) 2011-12-30
CR20110366A (es) 2011-08-29
EP2358689B9 (en) 2016-08-03
ME02331B (me) 2016-04-28
ZA201104659B (en) 2012-08-29
DOP2011000165A (es) 2011-06-30
CY1117178T1 (el) 2017-04-05
RS54370B9 (sr) 2020-01-31
KR20110091039A (ko) 2011-08-10
RS54370B1 (sr) 2016-04-28
MY150989A (en) 2014-03-31
PE20110588A1 (es) 2011-09-08
CN102300854A (zh) 2011-12-28
PL2358689T3 (pl) 2016-03-31
TWI436987B (zh) 2014-05-11
JP5640014B2 (ja) 2014-12-10
SI2358689T1 (sl) 2016-01-29
PT2358689E (pt) 2015-12-30
NZ593759A (en) 2012-07-27
WO2010064722A1 (en) 2010-06-10
CO6400140A2 (es) 2012-03-15
ECSP11011165A (es) 2011-07-29
CL2011001299A1 (es) 2012-01-13
EP2358689A1 (en) 2011-08-24
JP2012510467A (ja) 2012-05-10
ES2557304T3 (es) 2016-01-25
HK1161236A1 (zh) 2012-08-24
CA2745144C (en) 2017-10-03
EP2358689B1 (en) 2015-09-30
UY32281A (es) 2010-06-30
SG171426A1 (en) 2011-07-28
US8143258B2 (en) 2012-03-27
HRP20151370T1 (hr) 2016-01-15
DK2358689T3 (en) 2015-12-14
AU2009323274A1 (en) 2011-07-07
CA2745144A1 (en) 2010-06-10
KR101639092B1 (ko) 2016-07-12
HUE026491T4 (en) 2017-07-28
MX2011005836A (es) 2011-06-17
AR074435A1 (es) 2011-01-19
MA32911B1 (fr) 2011-12-01
EA019447B1 (ru) 2014-03-31
HUE026491T2 (en) 2016-06-28
BRPI0922109A2 (pt) 2020-09-01
TW201024272A (en) 2010-07-01
US20100216810A1 (en) 2010-08-26
AU2009323274B2 (en) 2015-09-17
SMT201500316B (it) 2016-01-08
US20120214855A1 (en) 2012-08-23

Similar Documents

Publication Publication Date Title
CN102300854B (zh) 作为抗癌剂的苯并噻唑衍生物
US8034812B2 (en) Imidazopyridazine derivative having kinase inhibitory activity and pharmaceutical agent thereof
JP5350247B2 (ja) 複素環化合物およびその用途
JP5579619B2 (ja) 複素環化合物およびその用途
CN101541801A (zh) 稠杂环衍生物及其用途
WO2009119776A1 (ja) 縮合複素環誘導体およびその用途
HK1161236B (en) Benzothiazole derivatives as anticancer agents

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150107